Glucotrack receives ethics approval for 1-year CBGM clinical study in diabetes patients

Glucotrack, Inc.

Ethical approval from St. Vincent's Hospital Melbourne HREC for long-term CBGM study in type 1/2 diabetes.
Study plans up to 30 participants; initial 1-year evaluation, possible extension to 3 years.
First patient implants expected by July 2025; Principal Investigators Prof. David O'Neal and Assoc. Prof. Neale Cohen.
CBGM is implantable, measures blood glucose directly (vs interstitial fluid), no wearable component.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.